Med. praxi. 2024;21(2):88-91 | DOI: 10.36290/med.2024.012

Gliflozins - what's new in practise

MUDr. Jan Škrha jr., Ph.D.
3. interní klinika 1. LF UK a VFN, Praha

Gliflozins represent modern and complex acting drugs with emerging indications. Apart from antidiabetic effects, there is increasing evidence of cardioprotective and renoprotective benefits pushing gliflozins among the standard treatment of patients with heart failure or chronic kidney disease, often without diabetes. Several risks of gliflozins should be acknowledged before their initiation and proper patient education in risks and benefits should be a common part of this initiation process.

Keywords: gliflozins, heart failure, chronic kidney disease, euglycemic ketoacidosis, indications.

Received: February 23, 2024; Accepted: April 17, 2024; Published: May 17, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škrha J. Gliflozins - what's new in practise. Med. praxi. 2024;21(2):88-91. doi: 10.36290/med.2024.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta­‑analysis. BMJ Open. 2016 Feb 24;6(2):e009417. Go to original source... Go to PubMed...
    2. Velliou M, Polyzogopoulou E, Ventoulis I, et al. Clinical pharmacology of SGLT-2 inhibitors in heart failure. EXPERT Rev Clin Pharmacol. 2023 Feb 1;16(2):149-60. Go to original source... Go to PubMed...
    3. Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. In: Nelson MT, Walsh K, editors. ANNUAL REVIEW OF PHYSIOLOGY, VOL 83 [Internet]. Palo Alto: Annual Reviews; 2021 [cited 2024 Feb 22]. p. 503-28. Available from: https://www.webofscience.com/api/gateway?GWVersion=2 & SrcAuth=DOISource & SrcApp=WOS & KeyAID=10.1146%2Fannurev­‑physiol-031620-095920 & DestApp=DOI & SrcAppSID=EUW1ED0EDFNUapzXTYKbMuRSzrL4R & SrcJTitle=ANNUAL+REVIEW+OF+PHYSIOLOGY%2C+VOL+83 & DestDOIRegistrantName=Annual+Reviews. Go to original source...
    4. Nevola R, Alfano M, Pafundi PC, et al. Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. Rev Cardiovasc Med. 2022 Mar 17;23(3):106. Go to original source... Go to PubMed...
    5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug;377(7):644-57. Go to original source... Go to PubMed...
    6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. Go to original source... Go to PubMed...
    7. Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta­‑Analysis Cardio­‑Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co­‑transporter-2 inhibitors on kidney outcomes: collaborative meta­‑analysis of large placebo­‑controlled trials. Lancet Lond Engl. 2022 Nov 19;400(10365):1788-801.
    8. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-86. Go to original source... Go to PubMed...
    9. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023 Oct 1;44(37):3627-39.
    10. Elendu C, Elendu RC, Enyong JM, et al. Comprehensive review of current management guidelines of chronic kidney disease. Medicine (Baltimore). 2023 Jun 9;102(23):e33984. Go to original source... Go to PubMed...
    11. Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care. 2015 Sep;38(9):1638-42. Go to original source... Go to PubMed...
    12. Centre for Perioperative Care Diabetes Guideline Working, Group. Guideline for Perioperative Care for People with Diabetes Mellitus Undergoing Elective and Emergency Surgery [Internet]. Centre for Perioperative Care (CPOC); 2021 [cited 2024 Feb 22]. Available from: https://abcd.care/resource/jbds-03-management­‑adults­‑diabetes­‑undergoing­‑surgery­‑and­‑elective­‑procedures­‑improving.
    13. Šoupal J, Doležalová B, Flekač M, et al. Doporučení pro mezioborovou spolupráci při zahájení léčby SGLT-2 inhibitory z jiné než diabetologické indikace [Internet]. 2023. Available from: https://www.diab.cz/dokumenty/doporuceni_pro_mezioborovou_spolupraci.pdf.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.